Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis

Ng, 2009, Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up, Eur J Nucl Med Mol Imaging, 36, 12, 10.1007/s00259-008-0918-7

Ng, 2008, Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of 18F-FDG PET and extended-field multi-detector row CT, Neuroradiology, 50, 969, 10.1007/s00234-008-0426-2

Stroobants, 2003, Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer, Clin Lung Cancer, 4, 242, 10.3816/CLC.2003.n.005

Niikura, 2011, FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer, Oncologist, 16, 1111, 10.1634/theoncologist.2011-0089

Walker, 2001, Whole-body magnetic resonance imaging: techniques, clinical indications, and future applications, Semin Musculoskelet Radiol, 5, 5, 10.1055/s-2001-12923

Barkhausen, 2001, Whole-body MR imaging in 30 seconds with real-time true FISP and a continuously rolling table platform: feasibility study, Radiology, 220, 252, 10.1148/radiology.220.1.r01jn07252

Antoch, 2003, Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology, JAMA, 290, 3199, 10.1001/jama.290.24.3199

Whiting, 2003, The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews, BMC Med Res Methodol, 3, 25, 10.1186/1471-2288-3-25

Chu, 2006, Bivariate meta-analysis of sensitivity and specificity with sparse data: a general linear mixed model approach, J Clin Epidemiol, 59, 1331, 10.1016/j.jclinepi.2006.06.011

Reitsma, 2005, Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews, J Clin Epidemiol, 58, 982, 10.1016/j.jclinepi.2005.02.022

Jaeschke, 1994, Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group, JAMA, 271, 703, 10.1001/jama.1994.03510330081039

O'Neill, 2010, Prospective, blinded trial of whole-body magnetic resonance imaging versus computed tomography positron emission tomography in staging primary and recurrent cancer of the head and neck, J Laryngol Otol, 124, 1274, 10.1017/S0022215110001398

Squillaci, 2008, Staging of colon cancer: whole-body MRI vs. whole-body PET-CT—initial clinical experience, Abdom Imaging, 33, 676, 10.1007/s00261-007-9347-5

Chen, 2010, Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?, Magn Reson Imaging, 28, 613, 10.1016/j.mri.2010.02.009

Laurent, 2010, Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT, Eur J Radiol, 75, 376, 10.1016/j.ejrad.2009.04.059

Schmidt, 2005, High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system, Invest Radiol, 40, 743, 10.1097/01.rli.0000185878.61270.b0

Pfannenberg, 2007, Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma, Eur J Cancer, 43, 557, 10.1016/j.ejca.2006.11.014

Plathow, 2008, Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced non small cell lung cancer–initial results, Invest Radiol, 43, 290, 10.1097/RLI.0b013e318163273a

Yi, 2008, Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging, Radiology, 248, 632, 10.1148/radiol.2482071822

Ohno, 2008, Non-small cell lung cancer: whole-body MR examination for M-stage assessment–utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT, Radiology, 248, 643, 10.1148/radiol.2482072039

Schmidt, 2008, Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3T compared to FDG-PET-CT, Eur J Radiol, 65, 47, 10.1016/j.ejrad.2007.10.021

Ng, 2009, Pretreatment evaluation of distant-site status with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-tesla and FDG-PET-CT, Eur Radiol, 19, 1366, 10.1007/s00330-009-1504-5

Schmidt, 2009, Whole-body MRI at 1.5T and 3T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer, Eur Radiol, 19, 1366, 10.1007/s00330-008-1289-y

Ng, 2010, Comprehensive imaging of residual/recurrent nasopharynge -al carcinoma using whole-body MRI at 3T compared with FDG-PET-CT, Eur Radiol, 20, 2229, 10.1007/s00330-010-1784-9

Dellestable, 2011, Impact of whole body magnetic resonance imaging (MRI) in the management of melanoma patients, in comparison with positron emission tomography/computed tomography (TEP/CT) and CT], Ann Dermatol Venereol, 138, 377, 10.1016/j.annder.2011.02.023

Chan, 2011, 18F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study, Eur J Nucl Med Mo Imaging, 38, 1607, 10.1007/s00259-011-1824-y

Ng, 2011, PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma, Eur J Nucl Med Mol Imaging, 38, 996, 10.1007/s00259-011-1740-1

Deeks, 2001, Systematic reviews of evaluations of diagnostic and screening tests, 248

Jaeschke, 2002, Diagnostic tests, 121

Glas, 2003, The diagnostic odds ratio: a single indicator of test performance, J Clin Epidemiol, 56, 1129, 10.1016/S0895-4356(03)00177-X

Stahl, 2000, Comparison of different SUV based methods for monitoring cytotic therapy with FDG PET, Eur J Nucl Med Mol Imaging, 31, 1471, 10.1007/s00259-004-1626-6